Literature DB >> 1650152

Persistent generation of peptido leukotrienes in patients with the adult respiratory distress syndrome.

G R Bernard1, V Korley, P Chee, B Swindell, A W Ford-Hutchinson, P Tagari.   

Abstract

The time course of leukotriene generation in the adult respiratory distress syndrome (ARDS) was investigated by measurement of urinary leukotriene E4 (LTE4) excretion, the major urinary LT metabolite in humans. Sequential measurements were made in nine subjects entered into the study within 48 h of the onset of ARDS, defined by an arterial/alveolar PO2 ratio of less than 0.3 and radiographic evidence of diffuse bilateral pulmonary edema. Initial urinary LTE4 excretion was significantly elevated (1.250 +/- 0.050 ng/mg creatinine sulphate; n = 7) compared with a non-ARDS postoperative group (0.254 +/- 0.114 ng/mg; n = 5) and normal control subjects (0.035 +/- 0.010 ng/mg; n = 12). LTE4 excretion in the first 24 h was estimated to be 6.9 micrograms, representing a release of 0.1 micrograms/kg/h of peptido leukotrienes into the bloodstream. These values were physiologically important based on a comparison with the increased urinary LTE4 excretion observed after antigen-induced bronchoconstriction in allergic asthmatics (baseline LTE4, 0.06 +/- 0.04 ng/mg; postantigen, 0.56 +/- 0.14 ng/mg; 0.17 micrograms LTE4/24 h; n = 8). In subjects with ARDS, this pathologic LTE4 excretion persisted during a subsequent 5-day study period. Leukotriene E4 excretion was associated with persistent abnormalities in gas exchange, pulmonary edema, and lung compliance, suggesting an important role for peptido leukotrienes in the pathophysiology of ARDS.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1650152     DOI: 10.1164/ajrccm/144.2.263

Source DB:  PubMed          Journal:  Am Rev Respir Dis        ISSN: 0003-0805


  10 in total

Review 1.  Pulmonary diseases other than asthma as potential targets for antileukotriene therapy.

Authors:  M Peters-Golden
Journal:  Clin Rev Allergy Immunol       Date:  1999 Spring-Summer       Impact factor: 8.667

Review 2.  The measurement of leukotrienes in human fluids.

Authors:  J Y Westcott
Journal:  Clin Rev Allergy Immunol       Date:  1999 Spring-Summer       Impact factor: 8.667

3.  Constitutive activation of 5-lipoxygenase in the lungs of patients with idiopathic pulmonary fibrosis.

Authors:  J Wilborn; M Bailie; M Coffey; M Burdick; R Strieter; M Peters-Golden
Journal:  J Clin Invest       Date:  1996-04-15       Impact factor: 14.808

4.  Effect of abdominal trauma on hemorrhagic shock-induced acute lung injury in rats.

Authors:  Bulent Kilicoglu; Erol Eroglu; Sibel-Serin Kilicoglu; Kemal Kismet; Fusun Eroglu
Journal:  World J Gastroenterol       Date:  2006-06-14       Impact factor: 5.742

Review 5.  Lipid mediators as agonists for the resolution of acute lung inflammation and injury.

Authors:  Caroline Bonnans; Bruce D Levy
Journal:  Am J Respir Cell Mol Biol       Date:  2006-09-21       Impact factor: 6.914

6.  5-Lipoxygenase deficiency prevents respiratory failure during ventilator-induced lung injury.

Authors:  Pietro Caironi; Fumito Ichinose; Rong Liu; Rosemary C Jones; Kenneth D Bloch; Warren M Zapol
Journal:  Am J Respir Crit Care Med       Date:  2005-05-13       Impact factor: 21.405

7.  Assessment of the in vivo biochemical efficacy of orally active leukotriene biosynthesis inhibitors.

Authors:  P Tagari; C Brideau; C Chan; R Frenette; C Black; A Ford-Hutchinson
Journal:  Agents Actions       Date:  1993-09

8.  Effect of montelukast, a cysteinyl receptor antagonist, on myofibroblasts in interstitial lung disease.

Authors:  Elizabeth Fireman; Yehuda Schwartz; Abraham Mann; Joel Greif
Journal:  J Clin Immunol       Date:  2004-07       Impact factor: 8.317

9.  Pulmonary hypertension in infants with congenital heart defects: are leukotrienes involved?

Authors:  A Serraf; J P Gascard; J Bruniaux; C Labat; C Planche; C Brink
Journal:  Mediators Inflamm       Date:  1997       Impact factor: 4.711

Review 10.  Biomarkers in Pediatric ARDS: Future Directions.

Authors:  Benjamin E Orwoll; Anil Sapru
Journal:  Front Pediatr       Date:  2016-06-01       Impact factor: 3.418

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.